Target intelligence / Profile preview

Non-Thioredoxin messenger RNAs with partial seed complementarity (Non-TXN mRNAs)

Target
Non-TXN mRNAs
Molecular classification
Messenger RNA, Nucleic acid
01

Overview

Non-Thioredoxin (Non-TXN) mRNAs with partial seed complementarity represent a broad class of unintended genetic targets for RNA interference (RNAi) therapeutics originally designed to silence the Thioredoxin (TXN) gene. This phenomenon occurs when the 'seed region' of an siRNA or miRNA mimic—typically nucleotides 2 through 8—exhibits complementarity to sequences within the 3' untranslated regions (UTRs) of various cellular mRNAs other than the intended TXN transcript (Jackson et al., 2003). Binding of the RISC complex to these off-target sites can lead to mRNA degradation or translational inhibition, mimicking the natural regulatory mechanism of microRNAs (Birmingham et al., 2006). Because a single siRNA can potentially interact with hundreds of different transcripts through this seed-mediated mechanism, it poses a significant challenge for drug specificity and safety (Setten et al., 2019). These off-target effects can lead to false positives in functional genomics screens and unintended toxicities in clinical applications (Burchard et al., 2009). Strategies to mitigate these effects include chemical modifications of the siRNA backbone, such as 2'-O-methyl substitutions, to destabilize off-target binding (Jackson et al., 2006). Identifying and minimizing these interactions is a critical step in the development of RNA-based drugs to ensure therapeutic efficacy and patient safety.

Other names
siRNA off-targetsmiRNA-like off-targetsSeed-matched off-target mRNAsSeed-mediated off-target transcripts
02

Mechanism of action

These transcripts are silenced via the RNA-induced silencing complex (RISC) when an siRNA's seed region (nucleotides 2-8) binds to complementary sequences in their 3' untranslated regions (UTRs).

03

Biological functions

Protein synthesis templateGene expression regulation
04

Disease associations

Off-target toxicityUnintended gene silencing
05

Safety considerations

HepatotoxicityCellular toxicityUnintended phenotype changesSaturation of RISC machinery
06

Interacting drugs

siRNAs

2 more in the full profile.

07

Biomarkers

Transcriptome profilingRNA-seqReporter assays

Beyond the preview

Go deeper on Non-Thioredoxin messenger RNAs with partial seed complementarity (Non-TXN mRNAs).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Non-Thioredoxin messenger RNAs with partial seed complementarity (Non-TXN mRNAs).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call